Search

Your search keyword '"Gamma hydroxybutyrate"' showing total 28 results
Start Over Descriptor "Gamma hydroxybutyrate" Publisher comtex news network, inc.
28 results on '"Gamma hydroxybutyrate"'

1. Avadel Pharmaceuticals Announces FT218 Leadership Transition

Subjects
United States. Food and Drug Administration -- Officials and employees, Gamma hydroxybutyrate, Narcolepsy -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Sep 14, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Seasoned industry veteran and Avadel Board member, Mark McCamish, M.D., Ph.D., to work with management and provide direct leadership [...]

Published
2020

2. Avadel Pharmaceuticals to Present at BIO Digital

Subjects
Narcolepsy, Gamma hydroxybutyrate, Conferences and conventions, Media executives, Clinical trials, Cataplexy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Jun 08, 2020 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2020

3. Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Subjects
Narcolepsy, Gamma hydroxybutyrate, Web sites (World Wide Web), Cataplexy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Jun 01, 2020 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2020

4. Avadel Pharmaceuticals Announces Pricing of Public Offering

Subjects
United States. Securities and Exchange Commission, Stock offerings, Narcolepsy -- Care and treatment, Gamma hydroxybutyrate, Advertising executives, Securities offerings, Cataplexy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Apr 28, 2020 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2020

5. Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering

Subjects
United States. Securities and Exchange Commission, Stock offerings, Narcolepsy -- Care and treatment, Gamma hydroxybutyrate, Advertising executives, Securities offerings, Cataplexy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Apr 27, 2020 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2020

6. Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Subjects
United States. Food and Drug Administration, Clinical trials, Cataplexy -- Care and treatment, Medical research, Gamma hydroxybutyrate, Narcolepsy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Mar 25, 2020 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the [...]

Published
2020

7. Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds

Subjects
Private placements (Securities), Narcolepsy, Gamma hydroxybutyrate, Preferred stocks, Consultants (Persons), Cataplexy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Feb 21, 2020 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2020

8. Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Subjects
United States. Food and Drug Administration, Clinical trials, Cataplexy -- Care and treatment, Gamma hydroxybutyrate, Narcolepsy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Dec 17, 2019 (GLOBE NEWSWIRE via COMTEX) -- - - - A total of 212 patients enrolled in the REST-ON study exceeds the trial's enrollment target of 205 [...]

Published
2019

9. TILT Holdings Subsidiaries Jupiter Research and Blackbird Logistics to Exhibit at 2019 Marijuana Business Conference

Subjects
High technology industry -- Conferences, meetings and seminars -- Forecasts and trends, Marijuana -- Conferences, meetings and seminars -- Exhibitions -- Forecasts and trends, Retail trade, Gamma hydroxybutyrate, Technology, Backup software, Brand names, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Mass., Dec 10, 2019 (GLOBE NEWSWIRE via COMTEX) -- TILT Holdings Inc. ('TILT' or the 'Company') (CSE: TILT) (OTCQB: TLLTF), a foundational technology cannabis platform comprised of assets to [...]

Published
2019

11. Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Subjects
United States. Food and Drug Administration, Clinical trials, Gamma hydroxybutyrate, Cataplexy -- Care and treatment, Narcolepsy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Nov 25, 2019 (GLOBE NEWSWIRE via COMTEX) -- 205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible Topline data from the REST-ON [...]

Published
2019

12. Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

Subjects
Narcolepsy, Gamma hydroxybutyrate, Web sites (World Wide Web), Media executives, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Nov 21, 2019 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2019

13. Avadel Announces Resignation of Kevin Kotler from Board of Directors

Subjects
Corporate directors, Narcolepsy, Gamma hydroxybutyrate, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Oct 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today [...]

Published
2019

14. Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th

Subjects
United States. Food and Drug Administration, Gamma hydroxybutyrate, Medical centers, Sleep, Narcolepsy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Sep 24, 2019 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, for narcolepsy, [...]

Published
2019

15. Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019

Subjects
United States. Food and Drug Administration, Gamma hydroxybutyrate, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Sep 23, 2019 (GLOBE NEWSWIRE via COMTEX) -- -- FDA agrees with Company's proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly [...]

Published
2019

16. Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th

Subjects
United States. Food and Drug Administration, Gamma hydroxybutyrate, Medical centers, Sleep, Narcolepsy, Conferences and conventions, Banking, finance and accounting industries, Business, Montefiore Medical Center
Abstract

DUBLIN, Ireland, Sep 18, 2019 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, Director [...]

Published
2019

17. Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th

Subjects
United States. Food and Drug Administration, Conferences and conventions, Narcolepsy, Gamma hydroxybutyrate, Web sites (World Wide Web), Media executives, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Sep 17, 2019 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today [...]

Published
2019

18. 2.2 tonnes of liquid drugs seized in Anhui

Subjects
Bars (Drinking establishments), Searches and seizures, Karaoke, Gamma hydroxybutyrate, Business, general, General interest, News, opinion and commentary
Abstract

HEFEI, June 21, 2019 (Xinhua via COMTEX) -- Police in east China's Anhui Province cracked down a drug case and seized 29 suspects, local police said on Friday. A total [...]

Published
2019

19. Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference

Subjects
Conferences and conventions, Gamma hydroxybutyrate, Sleep, Narcolepsy, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland, Jun 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced it will present two posters [...]

Published
2019

21. JAZZ: Hot Stocks

Subjects
Gamma hydroxybutyrate, Drug approval, Valproic acid, News, opinion and commentary, Xyrem (Medication)
Abstract

Jan 18, 2017 (TheFlyOnTheWall.com via COMTEX) -- 07:44 EDT Jazz Pharmaceuticals citizen petition on Xyrem package insert granted|In response to a citizen petition on behalf of Jazz Pharmaceuticals to the [...]

Published
2017

22. JAZZ: Hot Stocks

Subjects
United States. Food and Drug Administration, Gamma hydroxybutyrate, Drug approval, Narcolepsy -- Drug therapy, News, opinion and commentary, Xyrem (Medication)
Abstract

Jan 17, 2017 (TheFlyOnTheWall.com via COMTEX) -- 17:35 EDT FDA approves first generic version of Xyrem - The U.S. Food and Drug Administration has approved the first generic version of [...]

Published
2017

23. Flamel Technologies doses first patient with sodium oxybate in REST-ON Phase III Trial of FT218 for excessive daytime sleepiness & cataplexy

Subjects
Flamel Technologies S.A. -- Product development, Clinical trials, Gamma hydroxybutyrate, Cataplexy -- Care and treatment, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Dec 20, 2016 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Flamel Technologies SA (Nasdaq:FLML ) reported on Friday the start of treatment of the first patient under its Rest-On Phase [...]

Published
2017

24. Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218

Subjects
United States. Food and Drug Administration, Clinical trials, Chlor-alkali industry -- Product development, Drug delivery systems -- Product development, Gamma hydroxybutyrate, Business, general, Business, regional
Abstract

LYON, FRANCE, Oct 06, 2016 (Marketwired via COMTEX) -- LYON, FRANCE--(Marketwired - Oct 6, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that its Irish subsidiary, Flamel Ireland Holdings, has [...]

Published
2016

25. Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218

Subjects
United States. Food and Drug Administration, Clinical trials, Chlor-alkali industry -- Product development, Drug delivery systems -- Product development, Gamma hydroxybutyrate, Business, Business, international, News, opinion and commentary
Abstract

LYON, FRANCE, Oct 06, 2016 (Marketwired via COMTEX) -- LYON, FRANCE--(Marketwired - Oct 6, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that its Irish subsidiary, Flamel Ireland Holdings, has [...]

Published
2016

26. JAZZ: Recommendations

Subjects
Gamma hydroxybutyrate, News, opinion and commentary, Xyrem (Medication)
Abstract

Apr 21, 2016 (TheFlyOnTheWall.com via COMTEX) -- 08:14 EDT Jazz Pharma to enter 'favorable' Xyrem settlement agreements, says Leerink|Leerink analyst Jason Gerberry says Jazz Pharmaceuticals and one of the Xyrem [...]

Published
2016

28. Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate

Subjects
United States. Food and Drug Administration, Flamel Technologies S.A., Gamma hydroxybutyrate, Pharmaceutical industry, Business, Business, international, News, opinion and commentary
Abstract

Byline: LYON, FRANCE, Mar 31, 2016 (Marketwired via COMTEX) -- Flamel Technologies (NASDAQ: FLML) today announced that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results